Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.

European review for medical and pharmacological sciences - 1 Jan 2020

Licito A, Marotta G, Battaglia M, Benincasa G, Mentone L, Grillo M R, De Lucia V, Leonardi G, Bignucolo A, Comello F, Di Francia R, De Lucia D

Abstract excerpt

OBJECTIVE: At present, several strategies for preventing neuromuscular pain in Type 2 Diabetes Mellitus (T2DM) have been investigated. Recently, findings on genetic variants associated with adverse events to statin-based therapy have been reported. The study aimed at measuring whether Pharmacogenomics (PGx) profile can affect neuromuscular pain in patients carrying T2DM and cardiovascular diseases. An extensive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Diseases
Share to Hypoglycemic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver-Specific Organic Anion Transporter 1

Share to Pain Measurement

Share to Pharmacogenetics

Share to Simvastatin

Share to Sulfonylurea Compounds

Source

Identifiers

PMID: 31957862
DOI: 10.26355/eurrev_202001_19948

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.PMID 31957862Read ↗

Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of StatinsSemantic proximity Read ↗

Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.Semantic proximity Read ↗

Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy.Semantic proximity Read ↗

Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.Semantic proximity Read ↗

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.Semantic proximity Read ↗

Statin myotoxicity: a review of genetic susceptibility factors.Semantic proximity Read ↗

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.Semantic proximity Read ↗

The genetics of statin-induced myopathy.Semantic proximity Read ↗

Causal association between antidiabetic drug targets and risk of Bell's palsy: A 2-sample Mendelian randomization study.Semantic proximity Read ↗

Genetic Polymorphisms in Drug Transporter Genes (ABCB1, OATP1B1) and Their Impact on Statin Pharmacokinetics and Myopathy RiskSemantic proximity Read ↗

Genetic polymorphisms in ABCB1 are correlated with the increased risk of atorvastatin-induced muscle side effects: a cross-sectional study.Semantic proximity Read ↗

Pharmacogenetics of Statin-Induced MyotoxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.